LIST OF TABLES

Table A	Performance Characteristics of FETAX	ES-6
Table B	Summary of FETAX Validation Studies	ES-10
Table 1a	Major Chemical Classes Evaluated with FETAX	3-3
Table 1b	Major Product Classes Evaluated with FETAX	3-4
Table 2	Smith et al. (1983) Suggested List of Substances/Conditions for <i>In Vitro</i> Teratogenesis Testing	3-6
Table 3	Teratogenicity/Embryolethality of Binary Mixtures Tested in FETAX (Dawson and Wilke, 1991a, b)	5-4
Table 4	Malformation Information for Ten Carboxylic Acid Mixtures Tested in FETAX (Dawson, 1991)	5-6
Table 5	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Results	6-4
Table 6	Performance Characteristics of FETAX, With Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Results	6-7
Table 7	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Teratogenicity Results	6-11
Table 8	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Species Teratogenicity Results by Chemical and Product Class - TI >1.5 Decision Criterion	6-15
<u>Table 9</u>	Performance Characteristics of FETAX, with and without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Species Teratogenicity Results by Chemical and Product Class - TI >3.0 Decision Criterion	6-16
Table 10	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Combined Rat, Mouse, and Rabbit Species Teratogenicity Results by Chemical and Product Class - MCIG/LC ₅₀ Decision Criterion	6-17

Table 11	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Individual Rat, Mouse, and Rabbit Species Teratogenicity Results
Table 12	Performance Characteristics of FETAX, With Metabolic Activation, compared to Individual Rat, Mouse, and Rabbit Species Teratogenicity Results
Table 13	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Individual Rat, Mouse, and Rabbit Species Teratogenicity Results
Table 14	Performance Characteristics of FETAX, Without Metabolic Activation, compared to Human Teratogenicity Study Results6-30
Table 15	Performance Characteristics of FETAX, With Metabolic Activation, compared to Human Teratogenicity Study Results6-34
Table 16	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Human Teratogenicity Study Results
Table 17	Performance Characteristics of FETAX, With and Without Metabolic Activation, compared to Human Teratogenicity Study Results by Chemical and Product Class
Table 18	FETAX Results Discordant with Reference Laboratory Mammal and/or Human Teratogenicity Results
Table 19	Substances Inducing Gut Miscoiling, Craniofacial Malformations, or Microencephaly in <i>X. laevis</i> Embryos6-56
Table 20	Substances Tested in FETAX With Metabolic Activation: Identification of Possible Metabolic Activation Requiring Substances 6-62
Table 21	Phase I Validation Study—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria
<u>Table 22</u>	Phase I Validation Study—Concordance Within the Same Laboratory in Obtaining a Significant FETAX Response Based on Single Decision Criteria

Table 23	Phase II Validation Study—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-7
Table 24	Phase II Validation Study—Concordance Within the Same Laboratory in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-7
Table 25	Phase III.1 Validation Study—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-9
Table 26	Phase III.1 Validation Study—Concordance Within the Same Laboratory in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-10
Table 27	Phase III.2 Validation Study—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-13
Table 28	Phase III.2 Validation Study—Concordance Within the Same Laboratory in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-14
Table 29a	Phase III.3 Validation Study Without Metabolic Activation—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria	7-18
Table 29b	Phase III.3 Validation Study With Metabolic Activation—Concordance among Laboratories in Obtaining a Significant FETAX Response Based on Single Decision Criteria 7-19	7-19
Table 30	Conclusions by Laboratory for Chemicals Tested Without Metabolic Activation as Determined Using Multiple Criteria (TI >1.5 plus MICG/LC ₅₀ <0.3)	7-22
Table 31	Conclusions by Laboratory for Chemicals Tested With Metabolic Activation as Determined Using Multiple Criteria (TI >1.5 plus MICG/LC ₅₀ <0.3)	7-23
Table 32	Using Multiple Criteria, Comparison of Consensus FETAX Conclusions, With or Without Metabolic Activation, to the Consensus Non-Human Mammalian Teratogenicity	
	Conclusions	7-24

Table 33	Metabolic Activation, Compared to the Consensus Non-Human Mammalian Teratogenicity Conclusions	7-25
Table 34a	Comparison of Coefficient of Variation (CV) Results for All Validation Studies—FETAX Without Metabolic Activation	7-29
Table 34b	A Comparison of Coefficient of Variation (CV) Results for All Validation Studies—FETAX With Metabolic Activation	7-30
Table 35	Assessment of FETAX Performance Compared to Laboratory Mammalian and Human Teratogenicity Data When Analysis Is Limited to Experienced LaboratoriesLimited Database	7-34
Table 36	Concordance between TI $>$ 1.5 and MCIG/LC ₅₀ $<$ 0.3 for All Validation Studies	7-39
Table 37	List of Test Chemicals for the ECVAM Validation Study of Three <i>In Vitro</i> Embryotoxicity Tests (Genschow et al., 1999)	11-7
Table 38	Summary of Results for Complex Fossil Fuel Mixtures using FETAX (Dumont et al., 1983)	16-8